Coronavirus disease (COVID-19) is a contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, which depletes B lymphocyte cells and therefore disables the production of neutralizing antibodies. The combined use of external anti-viral agents like convalescent plasma, IVIG and Remdesivir successfully helped the patient’s immune system to eradicate the virus without B-cell population recovery. In vitro studies showed that convalescent plasma is the main agent that helped in eradicating the virus.
All Keywords
【저자키워드】 SARS-CoV-2, Pneumonia, Immunocompromised, T lymphocytes, 【초록키워드】 COVID-19, coronavirus disease, convalescent plasma, Corona virus, coronavirus, Neutralizing antibodies, Remdesivir, immune system, severe acute respiratory syndrome Coronavirus, virus, IVIG, rituximab, Case report, anti-viral agent, lymphocyte, Patient, contagious disease, respiratory, disease, B lymphocyte, B-cell, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, difficulty, contagious, combined use, Cell, caused, treated, deplete, 【제목키워드】 Mediated, the SARS-CoV-2,
【저자키워드】 SARS-CoV-2, Pneumonia, Immunocompromised, T lymphocytes, 【초록키워드】 COVID-19, coronavirus disease, convalescent plasma, Corona virus, coronavirus, Neutralizing antibodies, Remdesivir, immune system, severe acute respiratory syndrome Coronavirus, virus, IVIG, rituximab, Case report, anti-viral agent, lymphocyte, Patient, contagious disease, respiratory, disease, B lymphocyte, B-cell, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, difficulty, contagious, combined use, Cell, caused, treated, deplete, 【제목키워드】 Mediated, the SARS-CoV-2,
코로나바이러스 감염증(COVID-19)은 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2)에 의해 발생하는 전염병입니다. 이 증례보고는 B림프구 세포를 고갈시켜 중화항체 생성을 억제하는 리툭시맙 치료로 인해 코로나 바이러스 퇴치에 어려움을 겪은 환자를 제시한다. 회복기 혈장, IVIG 및 Remdesivir와 같은 외부 항바이러스제의 병용은 환자의 면역 체계가 B 세포 집단 회복 없이 바이러스를 근절하도록 성공적으로 도왔습니다. 시험관 내 연구는 회복기 혈장이 바이러스 근절에 도움이 되는 주요 물질임을 보여주었습니다.